ArkBio recibe la autorización de comercialización en China para Aizhida para el tratamiento del TDAH

📩 info@dengyuemed.com
🔗https://dengyuepharma.com

#ADHD #TDAH #ArkBio #Aizhida #NMPA #Biotecnología #IndustriaFarmacéutica #InnovaciónMédica #SaludInfantil

ArkBio Launches Phase II Study for Innovative RSV Preventative Antibody AK0610 ArkBio has initiated a Phase II clinical trial for AK0610, a monoclonal antibody developed to prevent respiratory syncytial virus (RSV) infections in infants in China.

ArkBio Launches Phase II Study for Innovative RSV Preventative Antibody AK0610 #China #Shanghai #RSV #ArkBio #AK0610

WHO Adds ArkBio's Ziresovir to Priority Pediatric RSV Drug List, A First from China ArkBio's Ziresovir has been recognized by WHO in its PADO-RSV pediatric drug priority list, marking a milestone as the first Chinese antiviral drug for RSV.

WHO Adds ArkBio's Ziresovir to Priority Pediatric RSV Drug List, A First from China #China #Shanghai #RSV #ArkBio #Ziresovir

ArkBio's Azstarys Drug Application for ADHD Receives Priority Review from China NMPA Shanghai Ark Biopharmaceutical's Azstarys, a new ADHD treatment combining two active ingredients, has received Priority Review status in China, promising better management for patients.

ArkBio's Azstarys Drug Application for ADHD Receives Priority Review from China NMPA #China #Shanghai #ArkBio #Azstarys #ADHD_treatment

ArkBio Shares Promising Phase II Results for Novel IPF Treatment AK3280 ArkBio has announced positive Phase II results for AK3280, a novel treatment for idiopathic pulmonary fibrosis, indicating significant improvements in lung function.

ArkBio Shares Promising Phase II Results for Novel IPF Treatment AK3280 #IPF #ArkBio #AK3280